7697-23-6

Basic information

• Product Name: 2-Fluoro-4-methylbenzoic acid
• Synonyms: 2-FLUORO-4-METHYLBENZOIC ACID;RARECHEM AL BO 2237;4-Carboxy-3-fluorotoluene;2-Fluoro-p-toluic Acid;4-Carboxy-3-fluorotoluene, 2-Fluoro-p-toluic acid;Benzoic acid, 2-fluoro-4-methyl-
• CAS NO: 7697-23-6
• Molecular Formula: C₈H₇FO₂
• Molecular Weight: 154.14
• EINECS: 212-233-7
• Product Categories: Fluorin-contained Benzoic acid series;Aromatic Carboxylic Acids, Amides, Anilides, Anhydrides & Salts;Fluorine series
• Mol File: 7697-23-6.mol
• Article Data: 13

Chemical Properties

• Melting Point: 186-189°C
• Boiling Point: 271.7 °C at 760 mmHg
• Flash Point: 118.1 °C
• Appearance: /
• Density: 1.258 g/cm³
• Vapor Pressure: 21mmHg at 25°C
• Refractive Index: 1.404
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 3.44±0.10(Predicted)
• CAS DataBase Reference: 2-Fluoro-4-methylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoro-4-methylbenzoic acid(7697-23-6)
• EPA Substance Registry System: 2-Fluoro-4-methylbenzoic acid(7697-23-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36-37
• HazardClass: IRRITANT
• Hazardous Substances Data: 7697-23-6(Hazardous Substances Data)

Usage

Description

2-Fluoro-4-methylbenzoic acid is an organic compound characterized by the presence of a fluorine atom at the 2nd position and a methyl group at the 4th position on a benzene ring, with a carboxylic acid functional group. It is known for its potential applications in the synthesis of various pharmaceuticals and chemical compounds.

Uses

Used in Pharmaceutical Industry:
2-Fluoro-4-methylbenzoic acid is used as a key intermediate in the synthesis of tubulin inhibitors for antitumor agents. These inhibitors play a crucial role in the development of cancer treatments by targeting the microtubules involved in cell division, thereby inhibiting tumor growth and progression.

InChI:InChI=1/C7H3F5/c1-2-3(8)5(10)7(12)6(11)4(2)9/h1H3

Upstream product

• 124-38-9 carbon dioxide 
• 352-70-5 m-Fluorotoluene 
• 452-74-4 4-bromo-3-fluorotoluene 
• 76-02-8 trifluoroacetyl chloride 
• 95-78-3 2,5-Dimethylaniline 
• 89-62-3 4-methyl-2-nitroaniline 
• 53078-85-6 2-bromo-5-methylaniline 
• 5326-34-1 4-Bromo-3-nitrotoluene 
• 696-01-5 2-fluoro-1,4-dimethylbenzene 
• 865-47-4 potassium tert-butylate 
• 612-45-3 4-methyl-2-nitroacetanilide 

Downstream Products

• 477199-77-2 4-(bromomethyl)-2-fluorobenzoic acid 
• 1436420-71-1 (S)-methyl 2-(4-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenylcarbamoyl)-3-fluorobenzylamino)-3-hydroxypropanoate 
• 1436420-67-5 4-(((2-(1H-imidazol-5-yl)ethyl)(methyl)amino)methyl)-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2-fluorobenzamide 
• 1436420-62-0 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-4-((cyanomethylamino)methyl)-2-fluorobenzamide 
• 1436426-29-7 4-(bromomethyl)-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2-fluorobenzamide 
• 1436426-30-0 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-4-(chloromethyl)-2-fluorobenzamide 
• 1436422-39-7 4-((2-amino-2-oxoethylamino)methyl)-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2-fluorobenzamide 
• 1436422-33-1 N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2-fluoro-4-(piperazin-1-ylmethyl)benzamide 
• 1436421-67-8 (R)-4-((1-amino-3-hydroxy-1-oxopropan-2-ylamino)methyl)-N-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2-fluorobenzamide hydrochloride 
• 1436421-62-3 (R)-methyl 3-amino-2-(4-(4-chloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenylcarbamoyl)-3-fluorobenzylamino)propanoate 
• 1436421-49-6 N-(4,5-dichloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2-fluoro-4-((1,1-dioxothiomorpholin-4-yl)methyl)benzamide 
• 1436421-47-4 (S)-4-((1-amino-3-hydroxy-1-oxopropan-2-ylamino)methyl)-N-(4,5-dichloro-2-(4-(3,3,3-trifluoropropyl)piperazin-1-yl)phenyl)-2-fluorobenzamide 

Relevant articles and documents

Chemical synthesis method of 4-fluoro-2-methyl benzoic acid

The invention relates to a chemical synthesis method of 4-fluoro-2-methyl benzoic acid. According to the synthesis method, m-fluorotoluene and trichloroacetyl chloride are used as starting raw materials, and are subjected to a Friedel-Crafts acylation reaction under the catalytic action of anhydrous aluminum trichloride, hydrolysis and acidification are performed under an alkaline condition to obtain two isomers of 4-fluoro-2-methyl benzoic acid and 2-fluoro-4-methyl benzoic acid, and the isomers are separated through re-crystallizing to obtain the target product 4-fluoro-2-methylbenzoic acid.The method has the advantages of accessible raw materials, mild reaction conditions and low cost, and is suitable for industrial production.

Synthesis of aryl fluorides on a solid support and in solution by utilizing a fluorinated solvent

(Figure Presented) F for fast: The perfluorinated solvent C 6F14 is the key to a new variant of the BalzSchiemann reaction for the synthesis of fluorinated arenes. Triazenes are converted into fluoroarenes under mild con-ditions on a support and in solution (see scheme). The method is straightforward and inexpensive, and yields previously difficult-to-prepare fluoroarenes in high purity.

New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists

Vasopressin (AVP) is a hormone that stimulates an increase in water permeability through activation of V2 receptors in the kidney. The analogue of AVP, desmopressin, has proven an effective drug for diseases where a reduction of urine output is desired. However, its peptidic nature limits its bioavailability. We report herein the discovery of potent, nonpeptidic, benzylurea derived agonists of the vasopressin V2 receptor. We describe substitutions on the benzyl group to give improvements in potency and subsequent modifications to the urea end group to provide improvements in solubility and increased oral efficacy in a rat model of diuresis. The lead compound 20e (VA106483) is reported for the first time and has been selected for clinical development.